Apyx Medical (NASDAQ:APYX) will release its quarterly earnings report on Tuesday, 2026-03-10. Here's a brief overview for investors ahead of the announcement.

Analysts anticipate Apyx Medical to report an earnings per share (EPS) of $-0.06.

The market awaits Apyx Medical's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.

It's important for new investors to understand that guidance can be a significant driver of stock prices.

Earnings Track Record

In the previous earnings release, the company beat EPS by $0.05, leading to a 15.52% increase in the share price the following trading session.

Here's a look at Apyx Medical's past performance and the resulting price change:

Tracking Apyx Medical's Stock Performance

Shares of Apyx Medical were trading at $3.12 as of March 06. Over the last 52-week period, shares are up 202.35%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Discovering Apyx Medical: A Closer Look

Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.

Unraveling the Financial Story of Apyx Medical

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: Apyx Medical's remarkable performance in 3 months is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 12.1%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Apyx Medical's net margin is impressive, surpassing industry averages. With a net margin of -15.41%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Apyx Medical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -30.29%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Apyx Medical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -3.43%, the company showcases efficient use of assets and strong financial health.

Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 6.71, caution is advised due to increased financial risk.

To track all earnings releases for Apyx Medical visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.